Neoadjuvant PD1/PD-L1 Blockade Combined with Chemotherapy Associated with High Resectability and Pathological Responses in Borderline Resectable or Unresectable Stage III NSCLC By Ogkologos - June 3, 2025 499 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a multicentre cohort study Source RELATED ARTICLESMORE FROM AUTHOR ESMO launches new principles for humanising scientific reporting to strengthen the communication of cancer research Clinical Activity of Talazoparib Plus Enzalutamide Demonstrated in Patients with High-Volume mHNPC, but Without Clear Benefit Over Enzalutamide in Biomarker-Unselected Population FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma MOST POPULAR Aiming to support a robust regulatory ecosystem for driving cancer research... May 12, 2026 NGS Is Effective in Identifying Actionable Genetic Alterations for Investigational Targeted... April 13, 2022 FDA Grants Accelerated Approval to Sotorasib for KRAS G12C-mutated NSCLC June 4, 2021 New Safety Signal for Use of Ibrutinib in Combination with Rituximab... September 15, 2021 Load more HOT NEWS FDA Approves Alpelisib for PIK3CA-Related Overgrowth Spectrum Sodium Thiosulfate Prevents Cisplatin-Induced Hearing Loss in Some Children Man Who Lost His Mother to Breast Cancer Opens Resource Center... iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with...
